Research and Clinical Trials
The Maryland Comprehensive Heart and Vascular Center is constantly conducting new research to investigate the causes of heart disease and find new ways to treat it, thereby improving the care and treatments we offer our patients.
Several examples of the cutting-edge research being performed by Maryland Heart and Vascular Center experts are listed below.
Two Clinical Trials for HLHS Patients
Dr. Sunjay Kaushal, M.D., Ph.D., is leading research to address hypoplastic left heart syndrome (HLHS), a life-threatening congenital heart condition in newborn babies. If left untreated, HLHS is usually fatal in the first weeks of life. Currently there is no cure for this devastating condition; but, by way of two new clinical trials, Dr. Kaushal, the University of Maryland Children’s Hospital, and its team are preparing to take a major step to improve – and possibly save – the lives of our tiniest patients. Click here for more.
New Surgical Tool For Mitral Valve Repair Demonstrates Success in First Human Clinical Study
Device Simplifies Valve Repair, Avoids Open Heart Surgery
Researchers investigating a novel device to repair the mitral heart valve report 100 percent procedural success in a safety and performance study, the first such study done in humans. The image-guided device, based on technology developed at the University of Maryland School of Medicine, is deployed through a tiny opening in a beating heart, avoids open-heart surgery, automates a key part of the valve repair process, simplifies the procedure and reduces operating room time. The research is published in the journal Circulation.
Read more here
A Healthier Take on Muffins
It's hard to think of the typical muffin, often loaded with saturated fat and a high calorie count, as a healthy food option. But muffins made with healthier fats yielded unexpected health benefits during a first-of-its-kind clinical study at the University of Maryland School of Medicine, led by Michael Miller, MD.
Read more here
Novel Ways to Treat Atrial Fibrillation - Timm-Michael Dickfeld, M.D.
Dr. Dickfeld's research focuses on novel approaches to make the ablation of abnormal heart rhythm (arrhythmia) more successful, especially complex arrhythmias such as ventricular tachycardia and atrial fibrillation, which have had only moderate treatment success in the past.
In close collaboration with the Department of Radiology and Division of Nuclear Medicine, we are able to approach these abnormal heart rhythms in novel and comprehensive ways by using computer tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and three-dimensional ultrasound. This allows the physician to visualize the heart in completely new ways and can be used for the development of new treatment strategies. These novel concepts are being evaluated in computer simulations and animal studies and are partially already available to improve patient care.
Cardiac Allograft Vasculopathy Research Laboratory
Using models of cardiac transplantation, doctors investigate the role of tobacco exposure on rejection, cardiac allograft vasculopathy and renal failure by studying inflammatory and oxidative stress pathways. These studies will serve to pave the way for clinical studies of new biomarkers specific to tobacco smoke risk, provide insight toward novel targets of therapy and open the door for the clinical trials in the setting of chronic atherosclerosis and acute coronary syndromes.
Genetic Variation and Heart Failure - Stephen B. Liggett, M.D.
Dr. Liggett is at the forefront of researchers into genetic variations that may help explain the effectiveness of heart failure medications known as beta-blockers in different people.
a research team led by investigators at the University of Maryland School of Medicine in Baltimore and the Washington University School of Medicine in St. Louis concluded that a genetic variation, found predominantly in African Americans, protects some people with heart failure, enabling them to live longer than expected. See related news release for more information.
Previously, researchers at the University of Maryland School of Medicine in Baltimore and the University of Colorado School of Medicine in Denver identified a common genetic variation that could help determine whether a person with heart failure would benefit from beta-blockers, a class of drugs used to treat chronic heart failure. The findings are significant because it often takes several months to determine if a specific beta blocker is working for a patient.
"For the first time, we have a genetic test that will help guide us to the best treatment for individual patients with heart failure and provide what has been called personal medicine," says the study's principal investigator, Stephen B. Liggett, M.D., professor of medicine and physiology at the University of Maryland School of Medicine and director of its cardiopulmonary genomics program.
Niacin Plus Statin Vs. Statin - Michael Miller, M.D.
Does adding a form of long-acting niacin to one of the most common cholesterol lowering drugs do a better job of delaying the onset of heart attack, stroke, blocked arteries or death from cardiovascular disease? That is the question that University of Maryland cardiologists hope to answer as they participate in a national study. The study, called AIM-HIGH, is a multi-center, randomized, double-blind clinical trial that compares a combination of extended-release niacin plus simvastatin to simvastatin alone.
Michael Miller, MD, director of preventive cardiology at the University of Maryland Medical Center and associate professor of medicine at the University of Maryland School of Medicine is the study's principal investigator in Maryland.